132 related articles for article (PubMed ID: 23072342)
1. Toxic epidermal necrolysis in a child successfully treated with infliximab.
Scott-Lang V; Tidman M; McKay D
Pediatr Dermatol; 2014; 31(4):532-4. PubMed ID: 23072342
[TBL] [Abstract][Full Text] [Related]
2. Severe cutaneous adverse reactions to drugs.
Chia FL; Leong KP
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):304-9. PubMed ID: 17620821
[TBL] [Abstract][Full Text] [Related]
3. Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study.
Paquet P; Jennes S; Rousseau AF; Libon F; Delvenne P; Piérard GE
Burns; 2014 Dec; 40(8):1707-12. PubMed ID: 24726294
[TBL] [Abstract][Full Text] [Related]
4. A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin.
Arca E; Köse O; Erbil AH; Nişanci M; Akar A; Gür AR
Pediatr Dermatol; 2005; 22(4):317-20. PubMed ID: 16060867
[TBL] [Abstract][Full Text] [Related]
5. Pediatric toxic epidermal necrolysis treated successfully with infliximab.
Chafranska L; Saunte DM; Behrendt N; Nygaard U; Christensen RJ; Sand C; Jemec GB
Pediatr Dermatol; 2019 May; 36(3):342-345. PubMed ID: 30834560
[TBL] [Abstract][Full Text] [Related]
6. Levetiracetam-induced pediatric toxic epidermal necrolysis successfully treated with etanercept.
Estébanez A; Sáez-Martín LC; Muñoz JI; Silva E; Monrabal A; Monteagudo C; Ramón MD
Pediatr Dermatol; 2020 Jul; 37(4):701-705. PubMed ID: 32319121
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
Ririe MR; Blaylock RC; Morris SE; Jung JY
J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis.
Woolridge KF; Boler PL; Lee BD
Cutis; 2018 Jan; 101(1):E15-E21. PubMed ID: 29529123
[TBL] [Abstract][Full Text] [Related]
9. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis.
Fischer M; Fiedler E; Marsch WC; Wohlrab J
Br J Dermatol; 2002 Apr; 146(4):707-9. PubMed ID: 11966713
[No Abstract] [Full Text] [Related]
10. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes.
Tan SK; Tay YK
Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
Yang Y; Xu J; Li F; Zhu X
Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
[TBL] [Abstract][Full Text] [Related]
12. Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus.
Worsnop F; Wee J; Natkunarajah J; Moosa Y; Marsden R
Clin Exp Dermatol; 2012 Dec; 37(8):879-81. PubMed ID: 22548502
[TBL] [Abstract][Full Text] [Related]
13. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases.
Chen J; Wang B; Zeng Y; Xu H
Eur J Dermatol; 2010; 20(6):743-7. PubMed ID: 20952352
[TBL] [Abstract][Full Text] [Related]
14. Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab.
Kreft B; Wohlrab J; Bramsiepe I; Eismann R; Winkler M; Marsch WC
J Dermatol; 2010 Oct; 37(10):904-6. PubMed ID: 20860742
[No Abstract] [Full Text] [Related]
15. Infliximab/Plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis.
White JC; Appleman S
Pediatrics; 2014 Oct; 134(4):e1194-8. PubMed ID: 25246624
[TBL] [Abstract][Full Text] [Related]
16. Etanercept therapy for toxic epidermal necrolysis.
Paradisi A; Abeni D; Bergamo F; Ricci F; Didona D; Didona B
J Am Acad Dermatol; 2014 Aug; 71(2):278-83. PubMed ID: 24928706
[TBL] [Abstract][Full Text] [Related]
17. Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options.
Teo L; Tay YK; Liu TT; Kwok C
Singapore Med J; 2009 Jan; 50(1):29-33. PubMed ID: 19224081
[TBL] [Abstract][Full Text] [Related]
18. [Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. Review of 15 cases].
Molgó M; Carreño N; Hoyos-Bachiloglu R; Andresen M; González S
Rev Med Chil; 2009 Mar; 137(3):383-9. PubMed ID: 19621180
[TBL] [Abstract][Full Text] [Related]
19. Extensive hypertrophic scarring after toxic epidermal necrolysis in a child.
Kreft B; Lieser U; Haase R; Marsch WC; Wohlrab J
Pediatr Dermatol; 2014; 31(4):527-8. PubMed ID: 23025572
[TBL] [Abstract][Full Text] [Related]
20. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
Koh MJ; Tay YK
Curr Opin Pediatr; 2009 Aug; 21(4):505-10. PubMed ID: 19474732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
